EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 截至本公告日期，本公司董事會包括董事長兼執行董事張波洲先生；執行董事張小利女士、張俊峰先生及張光弟先生；非執行董事 Richard Chen MAO先生、李甄先生及張麗女士；以及獨立非執行董事何明光先生、郭紅岩女士、李建濱先生及寶山先生。 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 朝聚眼科醫療控股有限公司 | | 股份代號 | 02219 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月31日 | | 公告狀態 | 新公告 | | 股息信息 | | | ...

Financial Performance - The group's revenue decreased by 3.2% from RMB 1,405.5 million for the year ended December 31, 2024, to RMB 1,360.4 million for the year ended December 31, 2025[2]. - The group's profit before tax decreased by 2.5% from RMB 262.7 million to RMB 256.1 million, with a profit before tax margin increasing from 18.7% to 18.8%[2]. - The net profit decreased by 4.7% from RMB 186.2 million to RMB 177.4 million, with a net profit margin decreasing from 13.2% to 13.0%[2]. - The adjusted net profit under non-IFRS decreased by 7.3% from RMB 202.7 million to RMB 187.9 million, with the adjusted net profit margin decreasing from 14.4% to 13.8%[3]. - The gross profit margin decreased from 43.5% to 42.2%[7]. - The EBITDA under non-IFRS for the year ended December 31, 2025, was RMB 363.2 million, compared to RMB 374.1 million for the previous year[7]. - Revenue from consumer ophthalmic services decreased by 2.4% from RMB 706.4 million for the year ending December 31, 2024, to RMB 689.5 million for the year ending December 31, 2025, primarily due to pricing adjustments in response to intensified market competition[25]. - Revenue from basic ophthalmic services decreased by 4.3% from RMB 697.8 million for the year ending December 31, 2024, to RMB 667.6 million for the year ending December 31, 2025, mainly due to the impact of national medical insurance pricing reforms[28]. - Gross profit decreased by 6.1% from RMB 611.3 million for the year ending December 31, 2024, to RMB 573.9 million for the year ending December 31, 2025, with gross margin declining from 43.5% to 42.2%[30]. Operational Metrics - The number of ophthalmology hospitals and optical centers operated by the group increased to 31 and 32, respectively, with an increase of three optical centers compared to the previous year[4]. - Outpatient visits decreased from 1,137,742 in 2024 to 1,061,851 in 2025, while the average spending per visit increased from RMB 713 to RMB 764[9]. - Inpatient visits decreased from 72,120 in 2024 to 69,747 in 2025, with the average spending per visit decreasing from RMB 6,914 to RMB 6,354[9]. - The consumer ophthalmology services segment generated revenue of RMB 689.5 million in 2025, accounting for 50.7% of total revenue, compared to RMB 706.4 million and 50.3% in 2024[11]. - The basic ophthalmology services segment generated revenue of RMB 667.6 million in 2025, accounting for 49.1% of total revenue, down from RMB 697.8 million and 49.6% in 2024[11]. Expenses and Costs - The total operating expenses, including selling and administrative expenses, were RMB 377.6 million for the year ended December 31, 2025[7]. - Selling and distribution expenses decreased by 11.3% from RMB 124.6 million for the year ending December 31, 2024, to RMB 110.5 million for the year ending December 31, 2025, mainly due to reduced compensation for sales and marketing personnel[33]. - Administrative expenses decreased by 7.7% from RMB 237.5 million for the year ending December 31, 2024, to RMB 219.1 million for the year ending December 31, 2025, primarily due to the end of share-based payment amortization for certain management personnel[34]. - Financing costs increased by 14.0% from RMB 10.7 million for the year ending December 31, 2024, to RMB 12.2 million for the year ending December 31, 2025, mainly due to interest expenses from convertible bonds issued in December 2024[36]. - Income tax expenses increased by 2.9% from RMB 76.5 million for the year ending December 31, 2024, to RMB 78.7 million for the year ending December 31, 2025, primarily due to an increase in unrecognized deferred tax asset losses[37]. Strategic Initiatives - The company aims to expand its network across seven provinces and municipalities in China, providing a range of ophthalmic services and products[8]. - The company continues to invest in advanced ophthalmic equipment and new technologies to enhance service quality and patient safety, including the introduction of femtosecond laser-assisted cataract surgery equipment[15]. - The company is focusing on optimizing marketing activities, particularly through online channels, and enhancing patient management to maintain customer loyalty[13]. - The group plans to continue expanding its network in North China and aims to acquire and establish more hospitals and optical centers in the near future[21]. - The company has a plan to fully utilize the funds for establishing new hospitals by December 31, 2027[70]. Employee and Governance - As of December 31, 2025, the group has a total of 1,474 full-time medical professionals, including 324 doctors, 620 nurses, and 530 other professionals[17]. - The company has implemented a share incentive plan to reward and retain employees, effective from May 10, 2022[77]. - The company provides systematic training and education programs to ensure high-quality service delivery by its employees[78]. - The company has established an audit committee to provide independent opinions on financial reporting procedures and internal controls[67]. - The board of directors includes Chairman and Executive Director Mr. Zhang Bozhou, Executive Directors Ms. Zhang Xiaoli, Mr. Zhang Junfeng, and Mr. Zhang Guangdi[127]. Cash Flow and Investments - Cash and cash equivalents decreased by RMB 264.4 million in 2025, primarily due to net cash inflow from operating activities of RMB 339.4 million and net cash outflow from investing activities of RMB 460.6 million[45]. - The net cash flow from investing activities for 2025 was RMB (460.6) million, indicating significant capital expenditures[45]. - The company has no significant contingent liabilities or guarantees as of December 31, 2025[48]. - The company raised approximately HKD 1,599 million from its global offering, issuing 137,500,000 shares at HKD 10.60 each, with an additional 20,125,000 shares issued after the exercise of the over-allotment option[68]. - The company has allocated approximately HKD 90.31 million for upgrading its information technology systems[69]. Market Position and Recognition - The group has received various awards and recognitions in 2025, including being named a "National Civilized Unit" and receiving the "Outstanding Unit for Medical Service Capability Improvement" honor[18]. - The group is committed to providing charitable medical assistance and diagnostic services to vulnerable communities, enhancing its brand reputation[19]. - The group is involved in various charitable activities, including providing eye examinations and treatments for underprivileged groups[20]. - The group aims to strengthen its leading position in North China and improve its market position in key regions such as the Yangtze River Delta[23]. Future Outlook - The company plans to continue focusing on cost management and exploring new market opportunities to enhance future performance[87]. - The company has not identified any significant future investment or capital asset plans disclosed as of December 31, 2025[57].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 董事會會議日期 朝 聚 眼 科 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）董 事（「董 事」）會（「董事會」）謹 此 公 佈，董 事 會 會 議 將 於 二 零 二 六 年 三 月 三 十 一 日（星 期 二） 舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 集 團 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 之 全 年 業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有）。 承董事會命 朝聚眼科醫療控股有限公司 香 港，二 零 二 六 年 三 月 九 日 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 主 席 張波洲 Chaoju Eye Ca ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 朝聚眼科醫療控股有限公司 呈交日期： 2026年3月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 朝聚眼科醫療控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 1,520,000,000 | | HKD | | 0.00025 HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,520,000,000 | HKD | | 0.00025 HKD | | 380,000 | 本月底法定/註冊股本總額： HKD 380, ...

朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 變更香港主要營業地點 朝 聚 眼 科 醫 療 控 股 有 限 公 司 董 事（「董 事」，各 自 均 為 一 名「董 事」）會（「董事會」） 謹 此 宣 佈，本 公 司 香 港 主 要 營 業 地 點 將 變 更 為 香 港 中 環 港 景 街 1 號國際金融中 心一期 9 樓，由 二 零 二 六 年 三 月 一 日 起 生 效。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 主 席 張波洲 香 港，二 零 二 六 年 二 月 二 十 七 日 截 至 本 公 告 日 期，本 公 司 董 事 會 包 括 董 事 長 兼 執 行 董 事 張 波 洲 先 ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 朝聚眼科醫療控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 1,520,000,000 | | HKD | | 0.00025 HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,520,000,000 | HKD | | 0.00025 HKD | | 380,000 | 本月底法定/註冊股本總額： HKD 380, ...

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - The company will spend HKD 162,000 to repurchase 60,000 shares [1]

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback plan, intending to repurchase 60,000 shares at a cost of HKD 162,000 [1]